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A B S T R A C T
Purpose: Oxcarbazepine (OXC) is a promising alternative for patients who cannot tolerate carbamaze-
pine. Recently, however, it has been reported that OXC-induced cutaneous adverse drug reactions
(cADRs) are prevalent and may lead to drug discontinuation. Additionally, these reactions are thought to
be associated with HLA-B*1502. This study aims to investigate the incidence, features and risk factors of
OXC-cADRs, and to explore their relation to HLA-B alleles in Southern Han Chinese.
Methods: A prospective study was performed to investigate the incidence, features and risk factors of
OXC-cADRs, in which 252 new users were recruited. To examine the association between OXC-cADRs
and HLA-B alleles, 14 maculopapular eruption (MPE) cases, including 9 additional cases beyond this
prospective observation, were genotyped by PCR-SSP and sequencing. Thirty-ﬁve OXC-tolerant patients
served as controls.
Results: Five patients (2.0%) developed an OXC-cADR, and all were mild MPE. History of other AED
allergy (p = 0.005, OR = 121.23) and non-AED allergy (p = 0.006, OR = 59.92) were signiﬁcant risk factors
for OXC-cADRs in multivariate logistic regression analysis. Only one patient with OXC-MPE was positive
for HLA-B*1502; and the frequency of HLA-B*1502 in OXC-MPE did not differ signiﬁcantly from that in
OXC-tolerant controls. Four HLA-B*1302 alleles were detected in OXC-MPE cases, which was
signiﬁcantly different from that in general population of southern Han Chinese (p = 0.001, OR = 7.83).
Conclusions: The incidence of OXC-induced cADRs was low, and no severe reactions occurred. Patients
with a history of allergy are more susceptible to OXC-cADRs. No signiﬁcant association between HLA-
B*1502 and OXC-MPE was found. The associations between OXC-MPE and HLA alleles warrant further
studies.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Oxcarbazepine (OXC), a 10-keto analogue of carbamazepine
(CBZ), is indicated to be equally, if not more, effective in seizure
control as compared to CBZ.1 Similar to CBZ, OXC primarily exerts
its antiepileptic effect by blocking voltage-dependent sodiumAbbreviations: cADRs, utaneous adverse drug reactions; CBZ, carbamazepine;
DRESS, drug rash with eosinophilia and systemic symptoms; MPE, maculopapular
eruption; OXC, Oxcarbazepine; PCR-SSP, polymerase chain reaction with sequence-
speciﬁc primers; SJS/TEN, Stevens–Johnson syndrome/toxic epidermal necrolysis.
* Corresponding author at: Institute of Neuroscience and the Second Afﬁliated
Hospital of Guangzhou Medical University, Chang-gang-dong Road 250, Guangzhou
510260, China. Tel.: +86 20 34152625; fax: +86 20 34153378.
E-mail address: wpliao@tom.com (W.-P. Liao).
1 These authors contributed equally to this work.
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.06.014channels.1 OXC has been approved as a monotherapy or adjunctive
therapy for the management of partial and secondarily generalised
seizures. Early studies have demonstrated that the incidence of
cutaneous adverse drug reactions (cADRs) induced by OXC is less
than that induced by CBZ,2,3 making OXC a viable alternative for
patients who cannot tolerate CBZ. Recently, however, it has been
reported that OXC-related skin rashes are also prevalent, with an
incidence of 5–9%,4–6 and lead to drug discontinuation in almost all
patients who experienced such adverse reactions.5
The OXC-induced cADRs vary from mild maculopapular
eruption (MPE) to severe reactions, such as Stevens–Johnson
syndrome/toxic epidermal necrolysis (SJS/TEN)7,8 and drug rash
with eosinophilia and systemic symptoms (DRESS).9–11 The
underlying mechanism of these idiosyncratic reactions remains
unclear and has been suggested to be multifactorial.12 Potential
risk factors include age, gender, dosage, drug titration schedule,vier Ltd. All rights reserved.
Table 1
Demographic and clinical characteristics of patients with newly administration of
OXC (n = 252).
Age at the enrollment of this study, mean  SD (years) 21.7  15.7
Adult patients aged older than 14 years, n (%) 152 (60.3)
Male, n (%) 144 (57.1)
Maintenance dosage in adult patients, mean  SD (mg/day) 755.2  234.9
Maintenance dosage in pediatric patients, mean  SD
(mg/kg/day)
21.8  6.3
Comedication with other AEDs, n (%) 83 (32.9)
History of other AED allergy, n (%) 4 (1.6)
History of non-AED allergy, n (%) 5 (2.0)
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increasing interest has been focused on the role of HLA-B*1502 in
OXC-induced cADRs, which was initiated by the observation that
HLA-B*1502 may be associated with OXC-SJS/TEN8 and then
extended to OXC-MPE.13
To investigate the incidence, features and predictors of OXC-
induced cADRs, we performed a prospective observational study in
a Southern Han Chinese population, and subsequently conducted a
case-control study to examine the association between OXC-
induced cADRs and HLA-B alleles.
2. Patients and methods
2.1. Patients in the prospective observational study
This prospective observational study was conducted from
January 2008 to December 2011 at the Epilepsy Centre of the
Second Afﬁliated Hospital of Guangzhou Medical University. The
subjects initially consisted of 266 patients (108 children and 158
adults) who had a history of two or more partial seizures (with or
without secondary generalisation). None of these patients had
been treated with OXC prior to the study.
OXC was administered as a monotherapy in 172 patients with
newly diagnosed epilepsy or as an add-on drug in 94 patients who
were currently being treated with other AEDs. The dosages of
concomitant AEDs were kept stable in the ﬁrst 2 months of
adjunctive OXC administration. The same titration of OXC was
performed whether it was used as a monotherapy or an adjunctive
therapy. Adult patients (>14 years old) were given an initial dose
of 300 mg/day and titrated with a dose increase by 150 mg every
week until 600–1200 mg/day, depending on clinical efﬁcacy and
drug reactions. For children (14 years old), the initial dose was
8 mg/kg/day, and increased by 8 mg/kg every week until 20–
30 mg/kg/day according to the patient’s response. If the dose for a
child was higher than that for an adult based on body weight, the
dosage schedule of adult was used. Each patient was observed for
at least 3 months as the initial symptoms of cADRs most frequently
occurred within the ﬁrst 8 weeks of OXC administration.14 Patients
who took OXC for less than 3 months and stopped for any other
reason than a rash were excluded.
Patients who developed a cADR were evaluated by a
dermatologist. MPE was deﬁned as erythematous exanthema
without blistering or pustulation; the diagnosis of SJS and TEN was
based on Roujeau’s diagnostic criteria;15 and DRESS was char-
acterised by fever, rash, eosinophilia and systemic manifestation
(e.g., hepatitis and nephritis). The attribution of cADRs to OXC was
assessed by the treating epileptologist and dermatologist together.
The patient demographics, medical history, concomitant AEDs,
dates of onset and termination of OXC treatment, reasons for
termination and adjustments of the AEDs therapy were all
documented.
2.2. Patients in the case-control study
To examine the association between HLA-B alleles and OXC-
induced cADRs, we subsequently conducted a case-control
association study. As only 5 patients developed OXC-MPE at the
conclusion of the study, we collected additional 9 patients with
OXC-MPE beyond the patients in the prospective observational
study. These additional patients had experienced an MPE when
treated with OXC at their local community hospitals. The OXC-
tolerant control group consisted of 35 patients without a cADR
after 3 months of OXC administration. All participants were
unrelated and members of an ethnic Han Chinese population
indigenous to Southern China, including Guangdong and Hunan
Provinces. Additionally, we set up another normal control group, ofwhich the HLA-B allele frequencies came from the general
Southern Han Chinese,16 the Hong Kong and Guangzhou Han
Chinese population17 (http://www.allelefrequencies.net).
The study protocol was approved by the ethics committee of the
hospital, and written informed consent was obtained from all
participants.
2.3. HLA-B genotype
Genomic DNA was extracted from peripheral blood samples
using the QIARamp blood mini kit (Qiagen, Hilden, Germany). The
presence of HLA-B*1502 was identiﬁed by polymerase chain
reaction with sequence-speciﬁc primers (PCR-SSP) according to
our previous study.18 To obtain HLA-B four-digit allele genotypes
of all OXC-MPE cases and OXC-tolerant controls, samples were
sequenced using an ABI 3730 automated sequencer (PE Applied
Biosystems, Forster City, CA, USA). The forward and reverse primer
sequences were Bin1-TAF (50-TGGCGGGGGCGCAGGACCTGA-30) or
Bin1-CGF (50-TCGGGGGCGCAGGACCCGG-30) and Bin3-R (50-
CGGAGGCCATCCCCGGCGACCTAT-30). The HLA-B four-digit allele
type was determined by sequence alignment at http://www.e-
bi.ac.uk/imgt/hla/align.html and using the software vector NTI 6.0
(InforMax Inc., Gaithersburg, MD, USA).
2.4. Statistical analysis
Logistic regression analysis was used to explore the potential
risk factors for OXC-induced cADRs. Six independent factors,
including age, gender, weight, history of non-AED allergy, history
of other AED allergy and comedication, were tested. The p value for
signiﬁcance was based on the number of factors included in the
multivariate analysis. Therefore, if p value < 0.008 (0.05/6), the
predictor was considered signiﬁcant. Chi-square test and Fisher’s
exact test were carried out to analyse the association between
OXC-MPE and HLA-B alleles. To reduce bias in estimating the odds
ratio, whenever a zero-count cell was encountered, 0.5 was added
to all cells in a 2  2 table.19 Two-sided p-values <0.05 were
considered statistically signiﬁcant. All analysis was performed
using SPSS version 16.0 (SPSS, Chicago, IL, USA).
3. Results
3.1. Incidence, features and potential predictors of OXC-cADRs
In the 4-year observation period, 266 patients were initially
recruited, among whom 252 patients completed the study. Four
patients stopped OXC administration within the ﬁrst 2 months due
to uncontrolled seizures; and 10 patients were lost to follow-up.
The demographic and clinical characteristics of the 252 patients
are summarised in Table 1. Only 5 patients (5/252, 2.0%) developed
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No severe reactions such as SJS, TEN or DRESS occurred.
The onset of symptoms for all patients with OXC-MPE was
within the ﬁrst 30 days of OXC exposure (mean latency of 10.2
days), and the mean allergy dose of OXC was 435 mg/day (range
300–600 mg/day). OXC was immediately discontinued, and short-
term steroid or antihistamine was administered. These patients
improved and recovered within 2 weeks after discontinuation of
OXC without hospitalisation. The substitute AEDs included
topiramate (TPM), levetiracetam (LEV), valproate (VPA), as well
as CBZ which was carefully tried in 2 patients for seizure control.
No cross-sensitivity of AEDs-cADRs was found on any of these
patients. The age, gender, clinical manifestations and HLA-B
genotypes of the 5 patients with MPE are presented in Table 2.
To explore the potential risk factors for OXC-induced cADRs, we
performed a logistic regression analysis (Table 3). History of non-
ADE allergy was shown to be a signiﬁcant predictor of OXC-rash
(p = 0.006, OR = 59.92, 95% CI 3.13–1146.89). Another signiﬁcant
predictor was history of other AED allergy (p = 0.005, OR = 121.23,
95% CI 3.99–3686.59). A trend toward increased OXC-rash in older
patients was noted, which was shown by the fact that the 5
patients with OXC-MPE were all adults (age range 24–61 years,
Table 2); but neither age older than 14 years nor age as a continue
variable was signiﬁcant risk factor for OXC-rash (p = 0.996 and
p = 0.074 respectively). No other variables, including gender,
weight or comedication with other AEDs, were signiﬁcant in
multivariate analysis.
3.2. Association between OXC-MPE and HLA-B alleles
To study the potential association between OXC-MPE and HLA-
B alleles, we recruited 9 additional patients with OXC-MPE inTable 3
Factors inﬂuencing OXC-induced rash (n = 252).
Predictor N (with predictor) Rate of OXC rash in
patients with predictor
Female 108 1.9% 
Older than 14 yrs 152 3.3% 
Comedication 83 1.2% 
Non-AED allergy 5 20.0% 
Other AED allergy 4 25.0% 
Weight 252 Continuous variable 
a Signiﬁcant in multivariate analysis, p value was set at 0.008 (0.05/6).
Table 2
Demographic, clinical characteristics and HLA-B genotypes of patients with OXC-induc
Patient Sex Agea
(ys)
BW
(kg)
Allergy
history
Initial dose
(mg/day)
Fi
(m
Cases in the prospective study
1 M 24 51 Alcohol-MPE 300 52
2 F 34 49 – 300 30
3 M 61 67 – 300 60
4 F 24 45 – 300 45
5 M 30 59 CBZ-MPE 300 30
Extended cases beyond the prospective study
E1 F 10 30 – 75 45
E2 F 2 10 – 60 6
E3 F 22 44 – 150 60
E4 F 23 52 – 300 30
E5 M 26 74 CBZ-MPE 300 30
E6 M 9 34 – 150 30
E7 M 33 76 – 300 45
E8 M 9 29 CBZ-MPE 150 15
E9 M 4 17 CBZ-MPE 75 7
BW, body weight; CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; PHT, phe
a Age at development of MPE.addition to the patients in the prospective study. The HLA-B
genotypes, demographic and clinical features of the 9 additional
patients are listed in Table 2. Meanwhile, we genotyped 35 OXC-
tolerant controls, of which data was summarised in Supplemental
Table S1.
Only 1 of the 14 patients with OXC-MPE had the HLA-B*1502
allele. The frequency of HLA-B*1502 in patients with OXC-MPE (1/
28, 3.6%) was neither signiﬁcantly different from that in the OXC-
tolerant controls (p = 1.00, OR = 1.23, 95% CI 0.11–14.47) nor
different from that in normal controls (p = 0.699, OR = 0.46, 95% CI
0.06–3.51, Table 4).
Comparing the frequency of each HLA-B allele between the MPE
group and the tolerant group, no signiﬁcant differences were
found. However, when the general Southern Han population was
used as normal control, the frequency of HLA-B*1302 was found to
be statistically signiﬁcantly higher in the MPE group (p = 0.001,
OR = 7.83, 95% CI 2.32–26.41). Four rare alleles, HLA-B*1519,
B*1527, B*2709 and B*4804 were found in the OXC-MPE group,
signiﬁcantly different from that in the normal controls (Table 4).
4. Discussion
In this 4-year prospective observational study, the incidence of
OXC-induced cADRs was shown to be 2.0%, similar to the 2.7% in a
prescription-event monitoring study,20 but much lower than the
5.0–9.0% observed in other retrospective studies.4–6 No severe
cutaneous reactions occurred in the present study. The relatively
higher rash incidence in retrospective studies may be partially due to
their own limitations: a documented history of rash cannot always
be conﬁrmed or attributed to a certain drug, and not every case was
examined and classiﬁed by a physician at the time of the rash.Rate of OXC rash in
patients without predictor
p OR (95% CI)
2.1% 0.741 0.69 (0.07–6.47)
0.0% 0.996 –
2.4% 0.268 0.21 (0.01–3.30)
1.6% 0.006a 59.92 (3.13–1146.89)
1.6% 0.005a 121.23 (3.99–3686.59)
0.543 1.03 (0.94–1.14)
ed MPE.
nal dose
g/day)
Latency
(days)
Concomitant
drugs
Substitution
drugs
HLA-B
genotype
5 16 VPA TPM 2704/2704
0 2 – CBZ 1302/1302
0 23 – TPM 1527/4601
0 8 – LEV, CBZ 4001/4001
0 2 – VPA, TPM 1502/2709
0 35 – VPA 4001/4001
0 7 – VPA 4601/4601
0 29 – TPM 1302/4901
0 2 VPA – 1527/4001
0 1 VPA, PHT – 1501/5604
0 7 – VPA 1519/4804
0 7 – TPM 1302/5401
0 1 – VPA 5101/5101
5 1 TPM, VPA, LEV LTG 3905/4601
nytoin; TPM, topiramate; VPA, valproate; –, none.
Table 4
Frequencies of HLA-B alleles and their relations to OXC-induced MPE.
HLA-B alleles Frequency (%) MPE cases versus OXC-tolerant
controls
MPE cases versus normal
population controls
MPE (2n = 28) OXC-tolerant
controls (2n = 70)
Population controls
(2n = 528/1138/212)
OR (95% CI) p value OR (95% CI) p value
1302 4/28 (14.3) 4/70 (5.7) 11/528 (2.1)a 2.75 (0.64–11.87) 0.32 7.83 (2.32–26.41) 0.001*
1501 1/28 (3.6) 3/70 (4.3) 24/528 (4.5)a 0.83 (0.08–8.31) 1.00 0.78 (0.10–5.97) 1.000
1502 1/28 (3.6) 2/70 (2.9) 39/528 (7.3)a 1.23 (0.11–14.47) 1.00 0.46 (0.06–3.51) 0.699
1519 1/28 (3.6) 0/70 (0) 0/1138 (0)b 7.69 (0.30–194.59) 0.29 124.2 (4.94–3117.64) 0.024*
1527 2/28 (7.1) 0/70 (0) 1/528 (0.2)a 13.30 (0.62–286.29) 0.08 40.54 (3.56–461.64) 0.007*
2704 2/28 (7.1) 0/70 (0) 7/528 (1.3)a 13.30 (0.62–286.29) 0.08 5.73 (1.13–28.93) 0.071
2709 1/28 (3.6) 0/70 (0) 0/1138 (0)b 7.69 (0.30–194.59) 0.29 124.2 (4.94–3117.64) 0.024*
3905 1/28 (3.6) 0/70 (0) 3/1138 (0.3)b 7.69 (0.30–194.59) 0.29 14.01 (1.41–139.08) 0.093
4001 5/28 (17.9) 15/70 (21.4) 76/528 (14.4)a 0.80 (0.26–2.45) 0.69 1.29 (0.48–3.51) 0.817
4601 4/28 (14.3) 14/70 (20.0) 63/528 (11.9)a 0.67 (0.20–2.24) 0.51 1.23 (0.41–3.66) 0.940
4804 1/28 (3.6) 0/70 (0) 0/1138 (0)b 7.69 (0.30–194.59) 0.29 124.2 (4.94–3117.64) 0.024*
4901 1/28 (3.6) 0/70 (0) 1/212 (0.5)c 7.69 (0.30–194.59) 0.29 7.82 (0.48–128.59) 0.220
5101 2/28 (7.1) 4/70 (5.7) 26/528 (4.9)a 1.27 (0.22–7.36) 1.00 1.49 (0.33–6.60) 0.936
5401 1/28 (3.6) 0/70 (0) 13/528 (2.5)a 7.69 (0.30–194.59) 0.29 1.47 (0.19–11.63) 0.519
5604 1/28 (3.6) 0/70 (0) 1/528 (0.2)a 7.69 (0.30–194.59) 0.29 19.52 (1.19–320.54) 0.098
a From a southern Han Chinese population of 264 persons (Trachtenberg et al., 2007).
b From a Hong Kong Chinese population of 569 persons (http://www.allelefrequencies.net/; Gonzalez-Galarza FF et al., 2011).
c From a Guangzhou Han Chinese population of 106 persons (http://www.allelefrequencies.net/; Gonzalez-Galarza FF et al., 2011).
* p < 0.05 (two-sided) was statistically signiﬁcant.
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present study is possibly attributable to the low initial dose and
slow titration method. Previous studies have revealed that a high
initial dose and rapid titration may increase the risk of cutaneous
reactions.12,21 In a double-blind trial involving 87 patients
receiving OXC at either 300 mg/day or 2400 mg/day, the rash rate
in the low-dose group (2/46, 4.3%) was almost 2-fold lower than
that in the high-dose group (5/41, 12.2%).22 Thus, despite the inter-
individual variability, a low initial dose of 300 mg/kg (8 mg/kg/day
for children) and slow escalation of 150 mg per week (8 mg/kg per
week for children) may be preferable for the majority of patients, at
least among the Chinese population.
Factors such as age, gender and history of allergy have been
indicated to be risk factors for AED-induced cADRs in general.12 For
instance, age younger than 13 years, female and comedication with
VPA will increase the risk of LTG-rash;23–25 while older age and
female are risk factors for CBZ- or PHT-related rashes.5,26 The
predictors of OXC-cADRs remain unclear. In the present study, we
found no signiﬁcant difference in age, gender and comedication
between patients with and without OXC-induced cADRs, consis-
tent with a previous study.5 One of 5 patients with non-AED allergy
histories (case 1) and 1 of 4 patients with other AED allergy
histories (case 5) developed OXC rash, which suggested that the
allergy histories were predictors of OXC-cADRs (signiﬁcant in
multivariate logistic regression analysis). A trend of increasing
proportion of cases with history of other AED allergy was also
found in the extended cases with OXC-MPE (3/9). Owing to the
small sample size, however, this observation warrants further
conﬁrmation in future studies with large samples. Actually, history
of non-AED allergy and history of other AED allergy have been
demonstrated to be signiﬁcant predictors of AED rash in a previous
study with 1890 patients involved.27 Cross-reactivity between
AEDs, especially aromatic AEDs such as OXC, CBZ, lamotrigine
(LTG) and phenytoin (PHT), has been quite a considerable problem
in optimising AEDs therapy with a 20–80% mutual risk.4,28,29 In this
study, we noticed that 4 patients with OXC-MPE had a prior CBZ-
induced MPE. Therefore, caution should be taken when prescribing
OXC for patients with a history of allergy, especially an allergy to
CBZ.
Recently, genetic susceptibility has appeared to be a predis-
posing factor for idiosyncratic reactions induced by AEDs.
Pharmacogenetic studies have indicated that HLA-B*1502 isstrongly associated with CBZ-induced SJS and TEN in Han
Chinese.30,31 Later on, an extended work suggested HLA-B*1502
may act as a common risk allele for aromatic AEDs-induced SJS and
TEN, including OXC-SJS/TEN.8 There was also a report on possible
association between HLA-B*1502 and OXC-MPE in a Han Chinese
population.13 In the present study, however, we failed to found a
signiﬁcant association between HLA-B*1502 and OXC-induced
MPE. Similar results have been revealed on associations between
HLA-B*1502 and CBZ-MPE,32,33 or LTG-MPE.18,34 Taken these
together, it may be considered that HLA-B*1502 is more
speciﬁcally associated with SJS/TEN but not MPE, which is
consistent with previous speculations.31,35
Other than HLA-B*1502, this study suggested HLA-B*1302 may
be potentially associated with OXC-MPE in this Han Chinese
population. The associations between OXC-MPE and four rare
alleles, B*1519, B*1527, B*2709 and B*4804 also warrant
clariﬁcation. Given a low incidence of OXC-MPE and a major
limitation of the sample size available for the analysis, we
performed a post hoc power analysis as in the previous study.36
On the condition that the prevalence of OXC-MPE was 2.0% in this
study, and a type 1 error rate (a) of 0.05, the present study had
approximately 80% power to detect an effect size of 28 for alleles
with a frequency of 1%. Thus, for HLA-B*1502 with a frequency of
7.3%, this study had approximately 80% or more statistical power
to suggest that there was no association between HLA-B*1502 and
OXC-MPE. Analogously, there was about 80% or more power to
suggest that HLA-B*1302 may have an association with OXC-MPE.
For the rare alleles with frequencies 0.2%, there was less than 80%
power to detect the association in Southern Han Chinese.
Nevertheless, evidences from this study did not support associa-
tions between HLA-B*1502 and OXC-MPE, though awaiting further
conﬁrmations. Based on this, the medical practice of not testing for
HLA-B*1502 before prescribing OXC was suggested, as it is
mandatory in populations at a genetically-determined and AED-
induced risk of SJS/TEN and DRESS, before prescribing the
homologous and possibly similarly efﬁcacious drug, CBZ.
Based on our prospective study that permits detailed follow-up
and proper diagnosis of emerging adverse events and their
potential cause, our ﬁndings reﬂect the relative true incidence
and features of OXC-induced cADRs in routine clinical practice.
However, the results obtained from the present analysis should be
interpreted with caution as they are limited by the low incidence of
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Larger sample studies are needed to determine whether the above
risk factors are truly associated with the development of OXC-
induced cADRs and to provide more accurate evaluation of their
impact.
To conclude, the incidence of cADRs induced by OXC was low in
these new users of OXC following this slow titration. All of the
reactions were mild MPE, and no severe reactions occurred. As a
predictor of OXC-cADRs, history of allergy needs attentions before
prescribing OXC. No signiﬁcant association between HLA-B*1502
and OXC-induced MPE was found in this Southern Han Chinese
population. Instead, we showed that HLA-B*1302 was potentially
associated with OXC-MPE, which warrants large sample studies
with four-digit genotyping.
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